Evaluation of Exenatide in Patients With Diabetic Neuropathy

Inclusion Criteria: * Type 2 diabetes treated with one or more oral agents * Persistent fasting glucose \> 140 mg/dl or HbA1c \> 7% * Stable and maximally effective doses of one or more oral agents for 3 months * Presence of diabetic peripheral neuropathy * Age between 18 and 70 years * No risk factors or other causes of neuropathy * Willingness and capacity to sign the Institutional Review Board approved consent form and cooperate with the medical procedures for study duration Exclusion Criteria: * Nursing mothers or pregnant women * A history of previous kidney, pancreas or cardiac transplantation * A past history of neuropathy (independent of diabetes) or with a disease known to be associated with neuropathy (e.g., hepatitis C, end stage renal disease, lupus) * Amputation of any part of either lower extremity for any reason or traumatic loss of any part of either lower extremity or congenital absence or severe deformity of lower extremity * HbA1c \> 10% * Participation in an experimental medication trial within 3 months of starting the study. * Undergoing therapy for malignant disease other than basal- or squamous cell carcinoma * Requiring long-term glucocorticoid therapy * Inability or unwillingness to comply with the protocol